Although the FLAURA study confirmed that there were promising survival benefits of treatment with third-generation EGFR-TKI as a first-line treatment, several real-world studies have found that sequential osimertinib use could also achieve satisfying clinical outcomes for advanced EGFR-mutant NSCLC patients harboring acquired T790M mutation after experiencing progressive disease under first- and second-generation EGFR-TKIs. Here, EGFR is linked to non-small cell lung carcinoma.